Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?

28.03.25 16:30 Uhr

Werte in diesem Artikel
Aktien

81,50 EUR -9,00 EUR -9,94%

Indizes

16.550,6 PKT -1.050,4 PKT -5,97%

It has been about a month since the last earnings report for Amedisys (AMED). Shares have added about 1.3% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, fresh estimates flatlined during the past month.VGM ScoresCurrently, Amedisys has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookAmedisys has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Amedisys und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Amedisys

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amedisys

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amedisys Inc.

Wer­bung

Analysen zu Amedisys Inc.

DatumRatingAnalyst
14.12.2018Amedisys Equal WeightBarclays Capital
30.10.2018Amedisys BuyThe Benchmark Company
19.03.2018Amedisys OutperformRBC Capital Markets
09.11.2017Amedisys HoldThe Benchmark Company
09.11.2017Amedisys Sector PerformRBC Capital Markets
DatumRatingAnalyst
30.10.2018Amedisys BuyThe Benchmark Company
19.03.2018Amedisys OutperformRBC Capital Markets
08.11.2017Amedisys BuyMizuho
02.11.2017Amedisys BuyThe Benchmark Company
03.05.2017Amedisys BuyMizuho
DatumRatingAnalyst
14.12.2018Amedisys Equal WeightBarclays Capital
09.11.2017Amedisys HoldThe Benchmark Company
09.11.2017Amedisys Sector PerformRBC Capital Markets
03.05.2017Amedisys HoldThe Benchmark Company
01.03.2017Amedisys NeutralMizuho
DatumRatingAnalyst
10.01.2012Amedisys underperformRobert W. Baird & Co. Incorporated

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amedisys Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen